Overview of 99mTc-anti-TNF-α scintigraphy: Diagnostic applications
Reports in Medical Imaging, cilt.7, sa.1, ss.1-3, 2014 (Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 7 Sayı: 1
- Basım Tarihi: 2014
- Doi Numarası: 10.2147/rmi.s39098
- Dergi Adı: Reports in Medical Imaging
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.1-3
- Anahtar Kelimeler: 99mTc tumor necrosis factor-α imaging, mAb, Monoclonal antibodies, Nuclear medicine
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Hatay Mustafa Kemal Üniversitesi Adresli: Evet
Özet
Tumor necrosis factor alpha (TNF-α) has a role in the pathogenesis of several inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. As TNF-α plays a role in the pathogenesis of different inflammatory diseases, anti-TNF-α agents (monoclonal antibodies [mAbs]) such as infliximab, adalimumab, and certolizumab have been developed and investigated for the treatment of these conditions. In recent years, these mAbs also have been used for diagnosis, monitoring, follow-up of disease activity, and therapy decision-making for inflammatory diseases, especially rheumatoid arthritis, after labeling with 99mTc. However, 99mTc-anti-TNF-α imaging might have severe adverse effects and is expensive. In contrast, scintigraphic imaging before therapy with radiolabeled mAbs may be a cost-effective solution for therapy decisions. © 2014 Elboga et al.